5 5 3 a r t I C l e S Sedatives target just a handful of receptors and ion channels 1,2 . But explaining how activating these receptors produces sedation presents a challenge 2 . In particular, do sedatives act at specific brain locations and circuitries or more widely? Some powerful sedatives, such as clonidine, guanfacine, xylazine and dexmedetomidine, are agonists at inhibitory metabotropic adrenergic α2 receptors. Among these, dexmedetomidine is being assessed as an alternative to benzodiazepines for sedating patients during intensive care 3 . It induces a state resembling non-rapid eye movement (NREM) sleep, with lowered body temperature and enhanced slow-wave activity in the neocortex [4] [5] [6] .
a r t I C l e S Sedatives target just a handful of receptors and ion channels 1, 2 . But explaining how activating these receptors produces sedation presents a challenge 2 . In particular, do sedatives act at specific brain locations and circuitries or more widely? Some powerful sedatives, such as clonidine, guanfacine, xylazine and dexmedetomidine, are agonists at inhibitory metabotropic adrenergic α2 receptors. Among these, dexmedetomidine is being assessed as an alternative to benzodiazepines for sedating patients during intensive care 3 . It induces a state resembling non-rapid eye movement (NREM) sleep, with lowered body temperature and enhanced slow-wave activity in the neocortex [4] [5] [6] .
At the circuit level it is unclear how α2 agonists induce sedation and loss of consciousness in humans or the presumed surrogate, LORR in animals 7 . The most popular proposal hinges on the selective inhibition by α2A (Adra2a) receptors, of noradrenergic neurons in the locus coeruleus (LC) [7] [8] [9] [10] [11] . These neurons fire during waking, fire less during sleep and their activity increases just before waking, suggesting that they promote wakefulness [12] [13] [14] . Although selectively stimulating LC neurons induces waking 15 , the converse is not true: acutely inhibiting LC neurons does not produce strong sleep, even after 1 h of stimulation 15 , an unexpected result if α2 agonists are supposed to acutely inhibit the LC to induce hypnosis. Moreover, dexmedetomidine still induces LORR in mice unable to synthesize noradrenalin (NA) 7, 16, 17 , although, without the endogenous ligand, α2A-receptor responses elsewhere become hypersensitized in the long term 7, 17 , making interpretation of this observation difficult 7 .
We hypothesized that the heavy, but arousable, nature of α2 agonist-induced sedation might be most similar to the NREM sleep experienced after sleep deprivation, so-called recovery sleep. In both cases, there is a strong urge to enter deep sleep. One place where these effects might come together is the preoptic (PO) hypothalamus. The PO area, a mixture of sleep-active, wake-active, temperature-sensitive and state-indifferent neurons [18] [19] [20] , houses circuitry that initiates and/or maintains sleep 18, 19, [21] [22] [23] and regulates body temperature 18 .
We first used siRNA knockdown, which established that, although dexmedetomidine-induced LORR depended on activating α2A receptors on LC neurons, sedation did not, suggesting that these states depend on different neuronal populations. We next explored whether the two types of deep sleep-the sedation imposed by dexmedetomidine and the recovery sleep following sleep deprivation, together with the accompanying drop in body temperature-required similar neural circuitry. For this, we combined TetTagging with DREADD pharmacogenetics (TetTag-DREADD) [24] [25] [26] . We 'tagged' neuronal ensembles in the PO hypothalamus that were activated during recovery sleep or dexmedetomidine-induced sedation, and then caused these tagged ensembles to be selectively reactivated using the hM 3 D q receptor and its ligand, clozapine-N-oxide (CNO) 27 . In both cases, reactivating the ensemble for sedation or recovery sleep produced sustained NREM sleep, together with a lower body temperature. We found that recovery sleep and α2 adrenergic receptor-induced sedation were not only similar behavioral states, but were both induced by activating similar neuronal populations in the PO hypothalamus.
RESULTS

Sedation and LORR require distinct neuronal populations
We examined dexmedetomidine's action at α2A receptors selectively in the LC, using acute knockdown of Adra2a transcripts, and a r t I C l e S determined how this affected sedation and LORR. We first selected two Adra2a shRNA sequences to use in vivo. For this, four putative Adra2a shRNA sequences (shAdra2a) were placed into a microRNA gene, mir30 (ref. 28) (Fig. 1a) . Two of the Adra2a hairpin sequences (shAdra2a 1 and shAdra2a 2 ) substantially reduced GFP expression from a reporter gene, Adra2a-IRES-gfp, coexpressed in HEK293 cells (Fig. 1a) . The dsRED-mir30-shAdra2a 1 , dsRED-mir30-shAdra2a 2 and dsRED-mir30-shscramble cassettes were then placed into adenoassociated virus (AAV) genomes, packaged and injected bilaterally into the LC (Fig. 1b) . In the following section, similar results were obtained with both shAdra2a sequences; all in vivo results are illustrated for shAdra2a 1 . The treated animals are termed LC-Adra2a-KD and LC-scramble. We obtained, on average, a knockdown to 46.3 ± 9.2% (mean ± s.e.) of control Adra2a transcript levels (t test, P < 0.004, compared with mRNA levels in the LC area of LCscramble mice). We prepared acute slices from brainstem of LCAdra2a-KD and LC-scramble mice and examined the electrophysiological responses of LC noradrenergic neurons to the α2 agonist dexmedetomidine (Fig. 1c) . Dexmedetomidine (1 µM), when applied to LC-scramble neurons, inhibited action potential firing, hyperpolarizing the membrane potential by 9.8 ± 2 mV (mean ± s.e.m., n = 6 cells), as shown previously for other noradrenergic α2 agonists 9, 10, 29 . However, in LC-Adra2a-KD neurons, dexmedetomidine failed to block action potential firing (Fig. 1c) and the membrane potential did not change significantly (P = 0.7, n = 7 cells). Thus, the knockdown of Adra2a gene expression by approximately 50% removed the ability of dexmedetomidine to silence LC neurons. This is consistent with studies on heterozygote Adra2a global knockout mice, which found that the Adra2a allele shows strong haplo-insufficiency, whereby even at a high dose of dexmedetomidine (433 µg per kg of body weight), dexmedetomidine-induced LORR in Adra2a knockout mice was abolished 30 .
We next injected a high dose of dexmedetomidine (400 µg per kg, intraperitoneal (i.p.)) into LC-scramble or LC-Adra2a-KD mice. All LC-scramble mice (n = 9) achieved LORR measured 10 min after dexmedetomidine injection; there was a concomitant large increase in delta power in the electroencephalogram (EEG; Fig. 1d ). By contrast, only 25% of LC-Adra2a-KD mice achieved LORR following dexmedetomidine injection (n = 8, Fisher's exact test, P = 0.0023); there was still an increase in EEG delta power in these mice, but it was about half that of control (scramble injected) mice (Fig. 1d) . Thus, we found that, in contrast with studies in mice with global dopamine-β-hydroxylase knockouts 16, 17 , but consistent with earlier proposals 11 , α2A receptors on LC neurons were needed for α2 adrenergic agonist-induced LORR, and their knock-down caused a reduction in dexmedetomidineinduced delta power. We next gave a separate group of LC-Adra2a-KD and LC-scramble mice lower doses of dexmedetomidine (12.5-100 µg per kg). Both groups of mice showed equal (P = 0.91) sedation (Fig. 1e) , becoming immobile and crouched, and with lowered heads. If prodded, they did respond briefly by walking, but then stopped. All sedated mice showed increases in EEG delta power (n = 5; Fig. 1d) , whether or not the α2A receptor had been knocked down. Thus, α2A receptor expression on LC neurons was not necessary for α2 adrenergic receptorinduced sedation, a conclusion that surprised us, given that it was necessary for LORR. We reasoned that α2A agonist-induced LORR and sedation are distinct states, involving different neuronal groups. Applying dexmedetomidine to scramble-expressing neurons hyperpolarized the membrane potential and the neurons stopped firing; by contrast, dexmedetomidine had no effect on the neurons from the LC-Adra2a-KD mice (P = 0.7, n = 7 cells). Fig. 2 and Supplementary  Fig. 1 ). We also investigated cFOS expression 2 h into the recovery sleep following 4 h of sleep deprivation ( Fig. 2 and Supplementary  Fig. 1 ). Although for both dexmedetomidine-induced sedation and during recovery sleep there were some cFOS-positive neurons in VLPO, we found many more activated cells in the wider PO area (lateral preoptic area, LPO; medial preoptic area , MPO) and in a cluster of areas just dorsal of the preoptic region, in the BST (for example, in the stria terminalis medial anterior and stria terminalis lateral dorsal), and in several septal nuclei: the ventral lateral septum (LSV) and in the septo-hypothalamic nucleus (SHy) (Fig. 2a-c) . Thus, the broadly similar patterns of induced cFOS during dexmedetomidine-induced sedation and during recovery sleep indicated that much of the PO region was a suitable location for TetTag-DREADD mapping [24] [25] [26] [27] to see if activating neurons in this location was sufficient for to induce the behavioral states of sedation and recovery sleep. We aimed to express, by TetTagging 24 , a cFos-promoter-inducible hM 3 D q -mCHERRY receptor gene 25, 27 selectively in the PO area of the hypothalamus. The excitatory hM 3 D q metabotropic receptor is uniquely activated by the ligand CNO 27 . By combining this receptor with cFos-dependent TetTagging, the gene encoding the hM 3 D q receptor is only turned on following neural activity and so records, or tags, ensembles of neurons that have been activated in vivo by a stimulus 25 . The neurons can then be reactivated later by systemic CNO, allowing sufficiency for the particular behavior 25 , sleep in this case, to be tested. TetTagging has been developed with transgenic mice 24, 25 . We set up the system using AAV genomes so that we could target the PO hypothalamus. Because of size constraints of the AAV genome, we generated two AAV viruses, one that contained the P cfos -tTA transgene, and another that contained the tet-operator promoter (P TRE-tight ) linked to an hM 3 D q -mCHERRY receptor reading frame (Fig. 3a) . With this method, before behavioral experiments are undertaken, the TetTag system is repressed with doxycycline in the diet. Doxycycline prevents tTA activating its target promoter, P TRE-tight , located in the second AAV genome; when doxycycline is removed, neural activity, such as that occurring in recovery sleep or dexmedetomidine-induced sedation, can drive the cFos promoter-linked tTA expression, which in turn can activate hM 3 D q -mCHERRY expression (Fig. 3a) .
Preliminary experiments revealed that, when AAV-P cfos -tTA and AAV-P TRE-tight -hM 3 D q -mCHERRY were co-injected, neurons were co-transduced. We therefore co-injected both the AAV-P cfostTA and AAV-P TRE-tight -hM 3 D q -mCHERRY bilaterally into LPO (LPO-TetTag-hM 3 D q mice) or centrally into the median PO, MnPO (MnPO-TetTag-hM 3 D q mice), the latter being an area in which neurons are particularly active in recovery sleep following sleep deprivation 19 (Fig. 3b) . We maintained the mice for 4 weeks on a doxycycline diet. Doxycyline was then removed from the diet to allow potential inducibility of the hM 3 D q -mCHERRY gene, and mice were given either a sedative dose of dexmedetomidine (100 µg per kg) i.p., a control saline injection i.p. or 4 h of sleep deprivation 2 d later, and then allowed recovery sleep. In about half of the cohort, the dexmedetomidine injection and sleep deprivation procedures were switched (Fig. 3b) . The order of these procedures made no difference to the results.
In the virally injected animals, we looked at activity-inducible hM 3 D q -mCHERRY patterns in the LPO and MnPO. We looked at TetTag gene expression in these areas before and after mice were given the sedative dose of dexmedetomidine (100 µg per kg) or sleep deprived and then killed during recovery sleep ( Fig. 3c and Supplementary Fig. 2 ). LPO-TetTag-hM 3 D q and MnPO-TetTaghM 3 D q brains were taken 2 h before, or 2 h after animals received dexmedetomidine or a control saline injection, or 2 h into recovery sleep. They were analyzed for mCHERRY expression. Before dexmedetomidine injection or sleep deprivation, but with no doxycycline npg a r t I C l e S present, there was a low, but detectable, level of P TRE-tight -hM 3 D q -mCHERRY expression this, we patch-clamped visually identified (mCHERRY positive) Tet-Tagged neurons found in acute PO slices after dexmedetomidineinduced sedation. In neurons that were TetTagged, we found that CNO induced an excitatory response (8 of 8 neurons in 3 animals) and was able to trigger action potential firing (Supplementary Fig. 6a ). The average depolarization was 10.2 ± 2.1 mV in response to 5 µM CNO. As expected, these results are consistent with the hM 3 D q receptor coupling to excitatory mechanisms 27 . After recording from the TetTagged neurons, we used single-cell quantitative PCR (qPCR) to determine their type: 84% were GABAergic (Gad1 and/or Gad2 expression) and the remaining were glutamatergic (Vglut2 expression) ( Supplementary Fig. 6b,c) .
Recapitulation of recovery sleep and sedation by CNO
The following sequence of results is illustrated with LPOTetTag-hM 3 D q and MnPO-TetTag-hM 3 D q mice first undergoing dexmedetomidine-induced sedation, followed by CNO treatment, then after a 1 month gap, 4-h sleep deprivation and recovery sleep followed by CNO treatment (Figs. 4 and 5) . Approximately 5 min after dexmedetomidine injection, the EEG of both LPO-TetTaghM 3 D q and MnPO-TetTag-hM 3 D q mice exhibited prominent and sustained NREM that lasted ~90 min relative to the mice given only saline (Figs. 4a and 5a) . All dexmedetomidine-injected mice became immobile (Fig. 4b) , but still had a righting reflex. We put mice back on the doxycycline diet for 4 d to repress the induction of further in scattered cells throughout the injected area in both the LPOTetTag-hM 3 D q mice and the MnPO-TetTag-hM 3 D q mice ( Fig. 3c and Supplementary Fig. 2 ). This basal transgene expression was also present with doxycycline. In LPO-TetTag-hM 3 D q brains, and consistent with the induction of the endogenous cFos gene (Fig. 2) , a wide area expressed hM 3 D q -mCHERRY receptors following systemic dexmedetomidine administration, stretching from the bed nucleus stria terminalis/lateral septum and septal hypothalamic nuclei in the dorsal part of the region, the whole LPO area and through to the VLPO and extended VLPO area at the base (Fig. 3c) . For recovery sleep, a similar LPO-P TRE-tight -hM 3 D q -mCHERRY expression pattern was found; this expression started to appear during the sleep deprivation period, and became stronger 2 h into recovery sleep (Fig. 3c) .
For the MnPO-TetTag-hM 3 D q brains, recovery sleep and dexmedetomidine-induced sedation both induced hM 3 D q -mCHERRY expression above basal levels in the MnPO area; however, there was a differential effect, as the gene induction was weaker following dexmedetomidine-induced sedation compared with that during recovery sleep (Supplementary Fig. 2) . In separate experiments, we determined that levels of the induced hM 3 D q -mCHERRY receptor protein persisted for at least 4 d post-stimulus (for example, dexmedetomidine-induced sedation or recovery sleep after sleep deprivation followed immediately by doxycycline in the diet; Fig. 3c and Supplementary Fig. 2 ), but that during the 4-week period following the first challenge, sleep-deprivation or dexmedetomidine-induced sedation, levels TetTag-hM 3 D q -mCHERRY expression fell back to baseline levels ( Fig. 3c and Supplementary Figs. 2-4) . CNO induced the expression of cFos protein in TetTagged hM 3 D qmCHERRY-positive neurons (Supplementary Fig. 5 ), suggesting that an excitatory response was generated in these neurons. To confirm npg a r t I C l e S TetTag-hM 3 D q receptors, injected them i.p. with CNO or saline and then recorded their EEG and behavioral responses (Figs. 4c,d and 5b) . The mice used in our study exhibited maximal periods of NREM sleep during the 'lights on' part of the cycle (Supplementary Fig. 7a,b) . All CNO injections were therefore carried out during this period when the mice were most active.
After CNO injection, the LPO-TetTag-hM 3 D q mice went into a state resembling sustained NREM sleep (Figs. 4c,d and 5b) . They moved little and their neocortical EEG developed powerful and sustained delta activity for about 90 min. Thus, dexmedetomidine-induced sedation was recapitulated by CNO injection.
Giving CNO to the MnPO-TetTag-hM 3 D q mice that were previously sedated with dexmedetomidine induced substantial delta power (high delta/theta ratio) in the EEG (Figs. 4c and 5c ), but these mice moved to a similar extent as the saline-or CNO-injected controls (Fig. 4d) . Thus, there was a notable disconnect between EEG and behavior. This suggests that the LPO area, but not the MnPO, contains neurons sufficient for full adrenergic α2 receptor-induced sedation.
Prior to the next stimulus, sleep deprivation followed by recovery sleep, LPO-TetTag-hM 3 D q and MnPO-TetTag-hM 3 D q mice were maintained on doxycycline for a further 4 weeks. CNO administration to these animals during the latter part of this time had no effect on the behavior or EEG, consistent with the decay of the hM 3 D qmCHERRY protein back to basal levels ( Fig. 3c and Supplementary  Fig. 2) . About a month after the first experiment (dexmedetomidineinduced sedation), the mice were removed from doxycycline and, 48 h later, instead of a sedative dexmedetomidine injection, the mice were sleep deprived and then allowed a period of recovery sleep (Fig. 4e) . During the recovery sleep, the EEG of both LPO-TetTag-hM 3 D q and MnPO-TetTag-hM 3 D q mice showed sustained NREM sleep (Figs. 4e  and 5d) . During a 30-min recording, mice in recovery sleep moved little (Fig. 4f) . After the period of sleep deprivation, the mice were placed back on doxycycline and, 4 d later, given a CNO or saline injection i.p. and their behavior and EEG responses were measured.
Both groups of CNO-injected mice, LPO-TetTag-hM 3 D q and MnPO-TetTag-hM 3 D q mice, had sustained delta power ~90 min following CNO administration (Figs. 4g and 5e,f) , and strong behavioral arrest (Fig. 4h) , showing that an ensemble of neurons had been activated in these areas that were sufficient to initiate and sustain recovery sleep. Given that these were the same group of animals that had earlier undergone dexmedetomidine-induced sedation and reactivation by CNO, it seems likely that dexmedetomidine-induced sedation and recovery sleep share similar mechanisms and circuitry for the LPO area. On the other hand, although MnPO seemed relevant for recovery sleep, where its re-activation seemed to be as effective as LPO's, MnPO had less of a role in dexmedetomidine-induced sedation.
Recapitulation of hypothermia by CNO Using TetTagging, we examined whether the neural circuitries in the LPO and MnPO areas were sufficient to trigger sedative or recovery sleep-induced hypothermia. Before any treatments, we checked that neither saline nor CNO injections caused a change in body temperature (Fig. 6a) . The body temperature of the mice was higher during the dark period when they were most active ( Supplementary Fig. 7c) ; as for the sedation experiments, all investigations of temperature were done during the dark period. 2 d after doxycycline removal, we gave LPO-TetTag-hM 3 D q and MnPO-TetTag-hM 3 D q mice the sedative dose of 100 µg per kg dexmedetomidine. This caused a strong a r t I C l e S hypothermia (Fig. 6a) , consistent with previous reports 6,32 . 4 d later, on a doxycycline diet, we then injected them with CNO. In the LPOTetTag-hM 3 D q animals, CNO reactivation of the dexmedetomidineinduced hypothalamic ensembles largely recapitulated the temperature drop (Fig. 6b) . There was, however, little effect in MnPO-TetTaghM 3 D q mice (Fig. 6c) . Thus, following dexmedetomidine sedation, activated neuronal ensembles in LPO, but not MnPO, are responsible for the hypothermia produced by this drug. A parallel group of LPO-TetTag-hM 3 D q and MnPO-TetTag-hM 3 D q mice were sleep deprived for 4 h and allowed recovery sleep. Sleep deprivation elevated their body temperature to about 38 °C; during the first few hours of recovery sleep, this temperature fell to that occurring during natural NREM sleep, about 36.5 °C (Fig. 6d and  Supplementary Fig. 7c) . 4 d later, we gave mice CNO. In both the LPO-and MnPO-TetTag-hM 3 D q groups, CNO treatment produced a substantial drop in body temperature (Fig. 6e,f) , comparable to, but somewhat larger than, that seen during recovery sleep (Fig. 6d) . Thus, as we found for the effects on delta power and immobility, both LPO and MnPO can contribute equal and parallel effects in producing hypothermia in recovery sleep.
Role of GABAergic neurons for the rapid onset of sedation
To test whether dexmedetomidine-induced sedation required GABAergic neurons in the LPO area, we deleted the vesicular GABA transporter (Vgat) gene by injecting AAV-Cre-2A-Venus bilaterally into the LPO of mice homozygous for a loxP-flanked Vgat gene 33 , Vgat lox/lox , to generate LPO-∆Vgat mice (Fig. 7a) . Control Vgat lox/lox mice were injected with AAV-GFP to give LPO-GFP mice.
1 month later, when given sedative doses of dexmedetomidine (100 µg per kg), and some 5 min after injection, control LPO-GFP mice showed the expected large increase in delta power in their EEG compared with that produced by saline injection (Fig. 7b) , they had sustained NREM lasting for ~90 min (Fig. 7c) , and in about 10 min after injection they had ceased moving (Fig. 7d) . By contrast, 10 min after i.p. injection of dexmedetomidine into LPO-∆Vgat mice, there was only a small shift of the EEG to delta frequencies (Fig. 7e) . This absence of effect was notable (Fig. 7b,e) . However, ~30 min after injection, the percentage of NREM in the LPO-∆Vgat mice was substantially higher than in saline-injected animals (Fig. 7f) , and the mice became sedated (Fig. 7g) , such that after 30 min they were as sedated as dexmedetomidine-injected LPO-GFP mice (Fig. 7c,f) . Thus, GABAergic neurons in the LPO area were required for rapidonset dexmedetomidine-induced sedation.
Controls for the TetTag-DREADD method
We did several controls for the specificity of the TetTag-DREADD system. First, CNO given alone to mice that had not received any AAV injections produced no behavioral effects, no change to the EEG npg a r t I C l e S (as noted previously 27 ) and no change in body temperature. Second, we found a low basal expression of the P TRE-tight -hM 3 D q transgene in the PO hypothalamic area of AAV-injected mice on doxycycline (Fig. 3c) . But even when we unlocked the transgene system by removing doxycycline for 2 d from the diet, and then giving CNO without any other treatments, nothing happened to the mice (Fig. 4c,d,g,h) . Evidently, strong stimulation of the relevant neurons is needed to induce the TetTag genes. Third, we co-injected the AAV-P cfos -tTA and AAV-P TRE-tight -hM 3 D q -mCHERRY viruses bilaterally into the superior colliculi (Supplementary Fig. 8a ), a region that is unlikely to be involved in either dexmedetomidine-induced sedation or recovery sleep after sleep deprivation. These SC-TetTag-hM 3 D q mice were then subjected to the full experimental procedure (Fig. 3b) : doxycycline repression for 1 month, doxycycline removal, dexmedetomidine-sedation followed by 4 d recovery and then CNO injection, and then, subsequently, the sleep deprivation and recovery sleep treatments, followed by CNO administration. No behavioral or EEG change was found ( Supplementary  Fig. 8b ) and there was little basal or induced hM 3 D q -mCHERRY expression seen in the colliculi, suggesting that the sleep-recapitulating effect of CNO is specific for the PO hypothalamus.
DISCUSSION
Selectively activating α2-adrenoreceptors is an effective way to induce deep, but arousable, sedation 7, 9, 10, 34 . The sleep-like qualities of this sedation hint that, by understanding how adrenergic α2 agonists work at the network level, we might learn more about circuitry regulating aspects of natural sleep. Global gene knockouts show that dexmedetomidine-induced sedation, hypothermia and LORR all depend on α2A receptors 9, 32 . Given that α2A receptor activation inhibits noradrenergic LC neurons 9 (Fig. 1c) and LC firing promotes wakefulness [13] [14] [15] , the view has been that α2-adrenergic agonists produce sedation by inhibiting the LC 7 . In many studies, sedation and LORR tend to be conceptually blended: sedation is considered a light or intermittent loss of consciousness, whereas LORR is a deeper version of this same state. We investigated this by acute knockdown of α2A receptors selectively from the LC. To our surprise, this did not alter dexmedetomidine's ability to induce sedation at low doses (<100 µg per kg), but did, on the other hand, abolish LORR at high concentrations (400 µg per kg). This suggests that these states, sedation and LORR, are generated by α2 agonist drugs influencing distinct circuitries; in particular, sedation induced by low-dose dexmedetomidine does not depend on inhibiting the LC.
We suggest that dexmedetomidine-induced LORR is not, in fact, the animal equivalent of deep loss of consciousness in humans, as usually assumed, but instead results from engaging the spinal cord mechanism that produces muscle atonia in REM sleep and cataplexy 35 . During wakefulness, GABAergic and glycinergic interneurons in the spinal cord and brainstem are inhibited by descending LC inputs 35 ; this descending inhibition is released during REM sleep to give muscle atonia 35 . Thus, over-stimulating the noradrenergic LC neurons optogenetically, probably silencing them by vesicle depletion, causes a cataplexy-like state with muscle atonia 15 . Similarly, we speculate that high-dose dexmedetomidine causes LORR by inhibiting LC neurons, which in turn releases interneuron inhibition of motor neurons.
Dexmedetomidine sedation and recovery sleep are similar In humans, the clinical use for dexmedetomidine is at the lower sedative doses. Thus, it is particularly important to understand the mechanism of this sedative component. A classic body of work shows Pan npg a r t I C l e S that the PO hypothalamic area regulates wakefulness, sleep and body temperature 18, 23, 36, 37 . Sleep-active and temperature-sensitive neurons are widespread in the PO area [18] [19] [20] . Indeed, we found that an extensive part of the PO hypothalamus and some neighboring dorsal structures express both endogenous cFOS and the cFos-dependent hM 3 D q -mCHERRY transgene during recovery sleep and after dexmedetomidine-induced sedation. It was not clear, however, if activating any of these neurons is sufficient to induce sleep or the accompanying decrease in body temperature found with these states. To test their sufficiency, we reactivated the induced TetTag ensembles with systemic CNO.
By artificially reactivating the neurons initially activated by a systemic low-dose of dexmedetomidine, we found that such LPO neurons are sufficient to induce both sedation (NREM sleep) and the accompanying strong hypothermia. The rapid induction of this sedation required GABAergic neurons in the LPO area, but full sedation could still emerge later when GABA release was blocked, implying additional mechanisms. Because some of these neurons release galanin 38 , this neuropeptide may also be involved. We also found that reactivating the same or similar groups of neurons in the LPO also mimicked recovery sleep and the drop in body temperature after sleep deprivation. Thus, TetTagging revealed that dexmedetomidine-induced sedation and recovery sleep are similar states, both requiring activation of neuronal ensembles in the LPO area. In the future, it will be interesting to disentangle the effects of sleep onset and body temperature decrease. Dexmedetomidine and sleep deprivation also induced TetTag-hM 3 D q expression in another PO nucleus, MnPO. Although reactivation of MnPO with CNO did fully recapitulate recovery sleep, it only partially recapitulated DEX-induced sedation. There was an interesting disconnect between a strong increase in the EEG delta/theta ratio and animal movementthe mice were not sleeping, but perhaps 'sleep walking' . This was also true with the hypothermia effects: although MnPO could recapitulate the temperature decrease seen in recovery sleep, no ensembles that regulate temperature were activated in MnPO by dexmedetomidine sedation.
The natural sleep rhythm over 24 h was not a sufficiently strong stimulus to induce the TetTag-DREADD neuronal ensembles, at least under our experimental protocol: their formation apparently required the stronger drivers of dexmedetomidine or recovery sleep following sleep deprivation. In basal conditions, CNO did not induce a change in the EEG compared with dexmedetomidine sedation and recovery sleep, and animals did not behaviorally enter sleep. Indeed, in mice with hM 3 D q receptors selectively, but continuously, expressed in GABAergic neurons in the PO hypothalamic area 39 , systemic CNO produced only a small increase in NREM sleep, and only during the day.
A dominant hypothesis has been that NA tonically inhibits sleepactive GABAergic neurons in the PO area during wakefulness that project to arousal nuclei 40, 41 . However, the TetTag method demonstrated that both α2 agonists and sleep deprivation induced NREM sleep and decreases in body temperature by locally exciting neurons in the preoptic area. One explanation for our results could be that adrenergic α2 agonists preferentially inhibit local GABAergic interneurons. These would in turn inhibit sleep-active GABAergic projection neurons less. Thus, following dexmedetomidine administration, the projection neurons would then fire more by dis-inhibition to induce sedation. However, a knockdown of Adra2a transcripts in the LPO did not alter the sedative effects of 100 µg per kg dexmedetomidine (Supplementary Fig. 9 ). Alternatively, dexmedetomidine could activate inhibitory α2A receptors on the terminals of inhibitory afferents coming into the PO area, for example, GABA inputs, or NA inputs from nuclei other than the LC. The reduced local release of GABA or NA into the PO hypothalamus would then allow dis-inhibition and excitation of the sleep-promoting neurons.
The biochemical mechanism for how recovery sleep is initiated and maintained remains a mystery. Candidate sleep homeostat molecules, which accumulate proportionally to the amount of sleep deprivation and act locally in the preoptic area, include PGD2 and adenosine 42 . Because hypothalamic-initiated recovery sleep and dexmedetomidineinduced sedation seem similar, another endogenous, but as yet unidentified, candidate sleep homeostat molecule might resemble an adrenergic α2 agonist in its properties.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
design and testing of Adra2a shRnAs. The mouse Adra2a coding region, including the start and stop codons, was obtained by PCR from the single exon adra2 gene in genomic DNA (primer sequences given in reference 43 ) and cloned into an expression plasmid pP cmv -IRES-gfp (Clontech) upstream of the IRES element, between XhoI and EcoRI sites, to give pP cmv -Adra2a-IRES-gfp (Fig. 1a) . We used the Invitrogen and pSM2 design (http://cancan.cshl.edu/RNAi_central/) algorithms to select shRNAs directed against the mouse Adra2a coding or 3′UTR regions. To express the shRNAs, we used the pPRIME system 28 . This generates micro-RNA-30 (mir30)-derived shRNAs and co-expression of a marker protein, such as dsRED, from the same transcript. The shRNA hairpin sequences were placed into the mir30 site of pPRIME-cmv-dsRed-FF3 (ref. The hairpin oligonucleotides were PCR amplified by VENT polymerase (NEB) using the pPRIME forward and reverse oligonucleotides with added XhoI and EcoRI sites underlined (forward: 5′-GATGGCTG-CTCGAG-AAGGTATAT-TGCTGTTGACAGTGAGCG-3′; reverse, 5′-GTCTAGAG-GAATTC-CGAGGCAGTAGGCA-3′), digested with XhoI and EcoRI, and inserted into the mir30 site of EcoRI/XhoI-digested pPRIME to generate the constructs shown in Figure 1a . To test knockdown efficiency of the shadra2 hairpins, HEK293 cells European Collection of Cell Cultures were co-transfected, using the calcium phosphate method, with pP cmv -Adra2a-IRES-gfp and the pPRIME-dsRED-mir30 plasmids. 16 h after transfection, cells were washed with PBS, and 48 h afterwards, the coverslips were then fixed, and mounted. generation of AAV shAdra2a1, shAdra2a2 kd and shscramble transgenes. To generate AAV transgene-expressing miRNAs, the dsRED-mir30-shAdra2a1, dsRED-mir30-shAdra2a2, and dsRED-mir30-shscramble inserts in pPRIME 28 were released by SbfI and PacI digestion, and cloned into the PstI and PacI sites in the polylinker of the AAV-genome plasmid pAM-flex 44 , where we had first changed the EcoRV site in the pAM-flex polylinker to PacI, to give ITR-cmv P enhancer/chicken β-actin -dsRED-mir30-shRNA-woodchuck post-translational regulatory sequence (WPRE)-bovine growth hormone polyadenylation signal (pA)-ITR. These constructs were packed into AAV capsids (see section below). generation of AAV tettag-dReAdd transgenes. The TetTag transgene components, cFos-tTA and P TRE-tight -hM 3 D q -mCHERRY, were placed into two separate AAV transgenes. As a building block, we started with the plasmid pAAV-ITR-P cmv/β-actin -iCre-2A-Venus-WPRE-pA-ITR 45 . A PacI site was first introduced just upstream of the CMV/β-actin promoter in this plasmid using Quick Change Mutagenesis (Agilent) (Primers 5′-CTG GAA GCT CCT TAA TTA ACG CTC TCC TGT TCC GAC C-3′ and 5′-GGT CGG AAC AGG AGA GCG TTA ATT AAG GAG CTT CCA G-3′), and the "P cmv/β-actin -Cre-2A-Venus" fragment then removed with PacI and NotI digestion. To generate the AAV-cFos-tTA construct, the cFos-tTA cassette, from a plasmid containing a cFos promoter/first intron −764/+918 fragment (P cFos ) linked to the tTA reading frame 24 (Addgene plasmid 34856; gift from M. Mayford, Scripps Research Institute), was PCR-amplified (the forward primer with a NotI site: 5′-GCATTCCACCACTGCGGCCGCTC ATCAGTTCCATAGG-3′ and reverse primer with a PacI site: 5′-GGTGCGG GCCTCTTCTTCTTAATTAAGCCAGACGGCCGCAGC-3′) and subcloned into the PacI/NotI digested Cre-Venus vector, to give pAAV-ITR-P cFos -tTA-WPRE-pA-ITR; For the generation of the pAAV-ITR-P TRE-tight -hM 3 D q -mCherry-WPRE-pA-ITR construct, we started with the plasmid pAAV-hSyn-double floxed hM 3 D q -mCHERRY 46 (a gift from Bryan L. Roth, University of North Carolina; Addgene plasmid 44361), which contains an inverted hM 3 D q -mCherry reading frame flanked by AscI and NheI sites. We PCR-amplified (forward primer hM 3 D q -NheI-F: 5′-CGAAGGTTATGGCTAGCCTTACTTGTACAGCTCG-3′; reverse primer hM 3 D q -AscI-R: 5′-CTTTATACGAAGTTATGGGCGCGCCAC
